Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2013 - 2026)

Amphastar Pharmaceuticals has reported Total Current Liabilities for 14 years, with the latest figure at $263.2 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 49.2% year-over-year to $263.2 million in Q2 2026; TTM through Jun 2026 was $263.2 million, a 49.2% increase from a year earlier, with the FY2025 full-year figure at $158.2 million, down 8.98% from the prior year.
• Total Current Liabilities was $263.2 million for Q2 2026 at Amphastar Pharmaceuticals, up from $164.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $263.2 million in Q2 2026, with the low at $94.9 million in Q4 2022.
• Average Total Current Liabilities over 5 years is $174.8 million, with a median of $169.1 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities surged 152.43% in 2023, then tumbled 45.49% in 2024.
• Over 5 years, Total Current Liabilities stood at $94.9 million in 2022, then soared by 137.62% to $225.4 million in 2023, then dropped by 22.91% to $173.8 million in 2024, then fell by 8.98% to $158.2 million in 2025, then jumped by 66.42% to $263.2 million in 2026.
• The last three Total Current Liabilities figures came in at $263.2 million (Q2 2026), $164.5 million (Q1 2026), and $158.2 million (Q4 2025), per Business Quant data.